Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose

Internal Medicine
Yasuhiro TsujiYoshihiro Yamamoto

Abstract

This study is the first case report of the treatment of methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis using therapeutic drug monitoring of the serum and wound exudate concentrations of linezolid in a renal dysfunction patient. In the present study, the serum trough concentration of linezolid was maintained between 2 and 7 μg/mL. Therapeutic drug monitoring dosage adjustments may be especially useful in patients with renal dysfunction and severe MRSA infection.

References

Feb 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M C FariñasJ González-Macías
Apr 1, 1996·Antimicrobial Agents and Chemotherapy·G E ZurenkoS J Brickner
Jan 23, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kinan AttassiMarcus J Zervos
Mar 1, 2002·European Journal of Clinical Pharmacology·T Lasher SissonN K Hopkins
Jun 14, 2002·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·B GårdlundJ Vaage
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·Michael E BrierGail L Jungbluth
May 25, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E S Dodds AshleyK S Kaye
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vin-Cent WuPo-Ren Hsueh
Jul 26, 2008·European Journal of Clinical Pharmacology·J Majcher-PeszynskaB Drewelow
Dec 23, 2008·International Journal of Antimicrobial Agents·Tadashi KosakaNaohisa Fujita
Jun 29, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yasuhiro TsujiYoshiharu Karube
Sep 9, 2011·Scandinavian Journal of Infectious Diseases·Yoichi HirakiYoshiharu Karube
May 4, 2012·The Journal of Antimicrobial Chemotherapy·Federico PeaMario Furlanut
May 21, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Yasuhiro TsujiHideto To
Aug 7, 2013·Journal of Clinical Pharmacology·Yasuhiro TsujiHideto To

❮ Previous
Next ❯

Citations

Jan 7, 2016·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Nobuyuki AshizawaYoshihiro Yamamoto
May 20, 2016·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·A Ambrosch
Feb 12, 2017·British Journal of Clinical Pharmacology·Yasuhiro TsujiYoshihiro Yamamoto
Feb 21, 2019·Expert Opinion on Pharmacotherapy·Daniele Roberto GiacobbeClaudio Viscoli
Sep 17, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshifumi NishiYoshihiro Yamamoto
Dec 20, 2021·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Takayuki DaishoYoh Takekuma

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.